{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:07:48Z","timestamp":1793336868414,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-021-02001-1","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T20:09:53Z","timestamp":1618517393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Development and Characterization of Excipient Enhanced Growth (EEG) Surfactant Powder Formulations for Treating Neonatal Respiratory Distress Syndrome"],"prefix":"10.1208","volume":"22","author":[{"given":"Susan","family":"Boc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A. M.","family":"Momin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale R.","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worth","family":"Longest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"issue":"1","key":"2001_CR1","first-page":"12","volume":"44","author":"J Dyer","year":"2019","unstructured":"Dyer J. Neonatal respiratory distress syndrome: tackling a worldwide problem. Pharm Ther. 2019;44(1):12.","journal-title":"Pharm Ther."},{"key":"2001_CR2","unstructured":"March of Dimes. Report Card. 2019. https:\/\/www.marchofdimes.org\/mission\/reportcard.aspx. Accessed 26 May 2020."},{"key":"2001_CR3","unstructured":"Martin JA, Hamilton BE, Osterman MJ. Births in the United States. 2018. NCHS Data Brief, no 346. Hyattsville, MD: National Center for Health Statistics. 2019. https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db346-h.pdf. Accessed 26 May 2020."},{"issue":"2","key":"2001_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000448985","volume":"111","author":"DG Sweet","year":"2017","unstructured":"Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European consensus guidelines on the management of respiratory distress syndrome-2016 update. Neonatology. 2017;111(2):107\u201325.","journal-title":"Neonatology."},{"issue":"2","key":"2001_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/joim.12845","volume":"285","author":"J Johansson","year":"2019","unstructured":"Johansson J, Curstedt T. Synthetic surfactants with SP-B and SP-C analogues to enable worldwide treatment of neonatal respiratory distress syndrome and other lung diseases. J Intern Med. 2019;285(2):165\u201386.","journal-title":"J Intern Med."},{"issue":"1","key":"2001_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/pr.2016.203","volume":"81","author":"S Sardesai","year":"2017","unstructured":"Sardesai S, Biniwale M, Wertheimer F, Garingo A, Ramanathan R. Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future. Pediatr Res. 2017;81(1):240\u20138.","journal-title":"Pediatr Res."},{"issue":"9803","key":"2001_CR7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(11)60986-0","volume":"378","author":"W G\u00f6pel","year":"2011","unstructured":"G\u00f6pel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet. 2011;378(9803):1627\u201334.","journal-title":"Lancet."},{"issue":"2","key":"2001_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.4187\/respcare.02189","volume":"58","author":"BK Walsh","year":"2013","unstructured":"Walsh BK, Daigle B, DiBlasi RM, Restrepo RD. AARC clinical practice guideline. Surfactant replacement therapy: 2013. Respir Care. 2013;58(2):367\u201375.","journal-title":"Respir Care."},{"issue":"1","key":"2001_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1542\/peds.2013-3442","volume":"133","author":"Committee on Fetus and Newborn","year":"2014","unstructured":"Committee on Fetus and Newborn. Respiratory support in preterm infants at birth. Pediatr. 2014;133(1):171\u20134.","journal-title":"Pediatr."},{"key":"2001_CR10","doi-asserted-by":"crossref","unstructured":"Notter RH. Introduction to surface tension and surfactants. In: Lenfant C (ed) Lung surfactants: basic science and clinical applications, vol. 149. NY: USA; 2000. p. 7\u201339.","DOI":"10.1201\/9781482270426"},{"issue":"2","key":"2001_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1164\/ajrccm.156.2.9609092","volume":"156","author":"R Schermuly","year":"1997","unstructured":"Schermuly R, Schmehl T, Gunther A, Grimminger F, Seeger W, Walmrath D. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury: impact on gas exchange. Am J Respir Crit Care Med. 1997;156(2):445\u201353.","journal-title":"Am J Respir Crit Care Med."},{"issue":"8","key":"2001_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.4155\/tde.13.72","volume":"4","author":"N El-Gendy","year":"2013","unstructured":"El-Gendy N, Kaviratna A, Berkland C, Dhar P. Delivery and performance of surfactant replacement therapies to treat pulmonary disorders. Ther Deliv. 2013;4(8):951\u201380.","journal-title":"Ther Deliv."},{"issue":"1","key":"2001_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12519-010-0201-4","volume":"7","author":"S Shah","year":"2011","unstructured":"Shah S. Exogenous surfactant: intubated present, nebulized future? World J Pediatr. 2011;7(1):11\u20135.","journal-title":"World J Pediatr."},{"key":"2001_CR14","doi-asserted-by":"crossref","unstructured":"Gupta S, Donn SM. Novel approaches to surfactant administration. Crit Care Res Pract. 2012;2012(278483).","DOI":"10.1155\/2012\/278483"},{"issue":"4","key":"2001_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1651-2227.2000.tb00084.x","volume":"89","author":"E Berggren","year":"2000","unstructured":"Berggren E, Liljedahl M, Winbladh B, Andreasson B, Curstedt T, Robertson B, et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr. 2000;89(4):460\u20134.","journal-title":"Acta Paediatr."},{"issue":"5","key":"2001_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/jamp.2009.0758","volume":"23","author":"NN Finer","year":"2010","unstructured":"Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Segal R. An open label, pilot study of Aerosurf\u00ae combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv. 2010;23(5):303\u20139.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"issue":"3","key":"2001_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/(SICI)1099-0496(199709)24:3<222::AID-PPUL9>3.0.CO;2-O","volume":"24","author":"G Jorch","year":"1997","unstructured":"Jorch G, Hartl H, Roth B, Kribs A, Gortner L, Schaible T, et al. To the editor: surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr Pulmonol. 1997;24(3):222\u20134.","journal-title":"Pediatr Pulmonol."},{"issue":"4","key":"2001_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000337354","volume":"101","author":"JJ Pillow","year":"2012","unstructured":"Pillow JJ, Minocchieri S. Innovation in surfactant therapy II: surfactant administration by aerosolization. Neonatology. 2012;101(4):337\u201344.","journal-title":"Neonatology."},{"key":"2001_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.earlhumdev.2019.05.005","volume":"134","author":"BG Sood","year":"2019","unstructured":"Sood BG, Cortez J, Kolli M, Sharma A, Delaney-Black V, Chen X. Aerosolized surfactant in neonatal respiratory distress syndrome: phase I study. Early Hum Dev. 2019;134:19\u201325.","journal-title":"Early Hum Dev."},{"key":"2001_CR20","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.403","volume":"2","author":"FJ Walther","year":"2014","unstructured":"Walther FJ, Hern\u00e1ndez-Juviel JM, Waring AJ. Aerosol delivery of synthetic lung surfactant. PeerJ. 2014;2:e403.","journal-title":"PeerJ."},{"issue":"2","key":"2001_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.18585\/inabj.v5i2.57","volume":"5","author":"DD Samsudin","year":"2013","unstructured":"Samsudin DD. Current issues and challenges in the use of aerosolized surfactant for respiratory distress syndrome in the newborns. Indones Biomed J. 2013;5(2):91\u2013100.","journal-title":"Indones Biomed J."},{"key":"2001_CR22","first-page":"131","volume":"8","author":"M Ibrahim","year":"2015","unstructured":"Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131\u20139.","journal-title":"Med Devices (Auckl)"},{"issue":"4","key":"2001_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.medengphy.2011.12.025","volume":"34","author":"N Islam","year":"2012","unstructured":"Islam N, Cleary MJ. Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery\u2013a review for multidisciplinary researchers. Med Eng Phys. 2012;34(4):409\u201327.","journal-title":"Med Eng Phys."},{"issue":"1","key":"2001_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1378\/chest.124.1.360","volume":"124","author":"MT Newhouse","year":"2003","unstructured":"Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 2003;124(1):360\u20136.","journal-title":"Chest."},{"issue":"6","key":"2001_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/adc.58.6.458","volume":"58","author":"AD Milner","year":"1983","unstructured":"Milner AD, Vyas H, Hopkin IE. Effects of artificial surfactant on lung function and blood gases in idiopathic respiratory distress syndrome. Arch Dis Childh. 1983;58(6):458\u201360.","journal-title":"Arch Dis Childh."},{"issue":"8211","key":"2001_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(81)90002-7","volume":"317","author":"CJ Morley","year":"1981","unstructured":"Morley CJ, Miller N, Bangham AD, Davis JA. Dry artificial lung surfactant and its effect on very premature babies. Lancet. 1981;317(8211):64\u20138.","journal-title":"Lancet."},{"issue":"6","key":"2001_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1089\/jamp.2012.0996","volume":"26","author":"G Pohlmann","year":"2013","unstructured":"Pohlmann G, Iwatschenko P, Koch W, Windt H, Rast M, de Abreu MG, et al. A novel continuous powder aerosolizer (CPA) for inhalative administration of highly concentrated recombinant surfactant protein-C (rSP-C) surfactant to preterm neonates. J Aerosol Med Pulm Drug Deliv. 2013;26(6):370\u20139.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"issue":"7","key":"2001_CR28","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1097\/CCM.0b013e3181dfcb3b","volume":"38","author":"C Ruppert","year":"2010","unstructured":"Ruppert C, Kuchenbuch T, Boensch M, Schmidt S, Mathes U, Hillebrand V, et al. Dry powder aerosolization of a recombinant surfactant protein-C\u2013based surfactant for inhalative treatment of the acutely inflamed lung. Crit Care Med. 2010;38(7):1584\u201391.","journal-title":"Crit Care Med."},{"issue":"6","key":"2001_CR29","first-page":"1","volume":"3","author":"FJ Walther","year":"2019","unstructured":"Walther FJ, Gupta M, Lipp MM, Chan H, Krzewick J, Gordon LM, et al. Aerosol delivery of dry powder synthetic lung surfactant to surfactant-deficient rabbits and preterm lambs on non-invasive respiratory support. Gates Open Res. 2019;3(6):1\u201323.","journal-title":"Gates Open Res."},{"issue":"5","key":"2001_CR30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/0021-8502(86)90035-2","volume":"17","author":"JJ Heyder","year":"1986","unstructured":"Heyder JJ, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005\u201315 \u03bcm. J Aerosol Sci. 1986;17(5):811\u201325.","journal-title":"J Aerosol Sci."},{"issue":"2","key":"2001_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/jps.21886","volume":"99","author":"K Cal","year":"2010","unstructured":"Cal K, Sollohub K. Spray drying technique. I: Hardware and process parameters. J Pharm Sci. 2010;99(2):575\u201386.","journal-title":"J Pharm Sci."},{"issue":"5","key":"2001_CR32","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s11095-007-9475-1","volume":"25","author":"R Vehring","year":"2008","unstructured":"Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999\u20131022.","journal-title":"Pharm Res."},{"key":"2001_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.powtec.2012.02.047","volume":"236","author":"MA Boraey","year":"2013","unstructured":"Boraey MA, Hoe S, Sharif H, Miller DP, Lechuga-Ballesteros D, Vehring R. Improvement of the dispersibility of spray-dried budesonide powders using leucine in an ethanol\u2013water cosolvent system. Powder Technol. 2013;236:171\u20138.","journal-title":"Powder Technol."},{"issue":"1","key":"2001_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/jps.21078","volume":"97","author":"D Lechuga-Ballesteros","year":"2008","unstructured":"Lechuga-Ballesteros D, Charan C, Stults CL, Stevenson CL, Miller DP, Vehring R, et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci. 2008;97(1):287\u2013302.","journal-title":"J Pharm Sci."},{"issue":"1-2","key":"2001_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijpharm.2017.06.004","volume":"528","author":"MAM Momin","year":"2017","unstructured":"Momin MAM, Sinha S, Tucker IG, Doyle C, Das SC. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis. Int J Pharm. 2017;528(1-2):107\u201317.","journal-title":"Int J Pharm."},{"issue":"1","key":"2001_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.powtec.2007.03.046","volume":"178","author":"PC Seville","year":"2007","unstructured":"Seville PC, Learoyd TP, Li HY, Williamson IJ, Birchall JC. Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol. 2007;178(1):40\u201350.","journal-title":"Powder Technol."},{"issue":"1","key":"2001_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/pharmaceutics12010024","volume":"12","author":"I Sibum","year":"2020","unstructured":"Sibum I, Hagedoorn P, Kluitman MP, Kloezen M, Frijlink HW, Grasmeijer F. Dispersibility and storage stability optimization of high dose isoniazid dry powder inhalation formulations with l-leucine or trileucine. Pharmaceutics. 2020;12(1):24.","journal-title":"Pharmaceutics."},{"issue":"7","key":"2001_CR38","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1080\/02786826.2011.566592","volume":"45","author":"P Worth Longest","year":"2011","unstructured":"Worth Longest P, Hindle M. Numerical model to characterize the size increase of combination drug and hygroscopic excipient nanoparticle aerosols. Aerosol Sci Technol. 2011;45(7):884\u201399.","journal-title":"Aerosol Sci Technol."},{"issue":"9","key":"2001_CR39","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/j.2042-7158.2012.01476.x","volume":"64","author":"M Hindle","year":"2012","unstructured":"Hindle M, Longest PW. Condensational growth of combination drug-excipient submicrometer particles for targeted high-efficiency pulmonary delivery: evaluation of formulation and delivery device. J Pharm Pharmacol. 2012;64(9):1254\u201363.","journal-title":"J Pharm Pharmacol."},{"issue":"11","key":"2001_CR40","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1007\/s11095-013-1123-3","volume":"30","author":"L Golshahi","year":"2013","unstructured":"Golshahi L, Tian G, Azimi M, Son YJ, Walenga R, Longest PW, et al. The use of condensational growth methods for efficient drug delivery to the lungs during noninvasive ventilation high flow therapy. Pharm Res. 2013;30(11):2917\u201330.","journal-title":"Pharm Res."},{"issue":"1-2","key":"2001_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijpharm.2013.01.003","volume":"443","author":"YJ Son","year":"2013","unstructured":"Son YJ, Longest PW, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Int J Pharm. 2013;443(1-2):137\u201345.","journal-title":"Int J Pharm."},{"issue":"19","key":"2001_CR42","doi-asserted-by":"publisher","first-page":"11003","DOI":"10.1021\/la801497d","volume":"24","author":"B Erickson","year":"2008","unstructured":"Erickson B, DiMaggio SC, Mullen DG, Kelly CV, Leroueil PR, Berry SA, et al. Interactions of poly (amidoamine) dendrimers with Survanta lung surfactant: the importance of lipid domains. Langmuir. 2008;24(19):11003\u20138.","journal-title":"Langmuir."},{"key":"2001_CR43","unstructured":"Survanta\u00ae [package insert]. AbbVie Inc., North Chicago, IL; 2012. http:\/\/www.rxabbvie.com\/pdf\/survanta_pi.pdf. Accessed July 2015."},{"key":"2001_CR44","unstructured":"Boc S. Aerosolized surfactants: formulation development and evaluation of aerosol drug delivery to the lungs of infants. 2018. https:\/\/scholarscompass.vcu.edu\/etd\/5577\/."},{"key":"2001_CR45","doi-asserted-by":"crossref","unstructured":"Li D, Xiong X, Bai Q, Yang W, Zhao R, Zhang A. Development and validation of an LC-MS\/MS method for quantification of dipalmitoylphosphatidylcholine as a promising biomarker for renal failure in urine. J Chin Pharm Sci. 2015;24.","DOI":"10.5246\/jcps.2015.02.008"},{"issue":"1-2","key":"2001_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijpharm.2016.04.038","volume":"506","author":"BB Eedara","year":"2016","unstructured":"Eedara BB, Tucker IG, Das SC. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis. Int J Pharm. 2016;506(1-2):174\u201383.","journal-title":"Int J Pharm."},{"issue":"6","key":"2001_CR47","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1208\/s12249-014-0182-z","volume":"15","author":"SA Meenach","year":"2014","unstructured":"Meenach SA, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. High-performing dry powder inhalers of paclitaxel DPPC\/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies. AAPS PharmSciTech. 2014;15(6):1574\u201387.","journal-title":"AAPS PharmSciTech."},{"issue":"4","key":"2001_CR48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/jamp.2017.1424","volume":"31","author":"D Farkas","year":"2018","unstructured":"Farkas D, Hindle M, Longest PW. Development of an inline dry powder inhaler that requires low air volume. J Aerosol Med Pulm Drug Deliv. 2018;31(4):255\u201365.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"issue":"3","key":"2001_CR49","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0307-4412(98)00091-0","volume":"26","author":"M Gugliotti","year":"1998","unstructured":"Gugliotti M, Politi MJ, Chaimovich H. A simple surface tension method for demonstrating the L\u03b2-L\u03b1 transition in biological membranes. Biochem Educ. 1998;26(3):233\u20138.","journal-title":"Biochem Educ."},{"issue":"2","key":"2001_CR50","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1529\/biophysj.103.034280","volume":"87","author":"HV Ly","year":"2004","unstructured":"Ly HV, Longo ML. The influence of short-chain alcohols on interfacial tension, mechanical properties, area\/molecule, and permeability of fluid lipid bilayers. Biophys J. 2004;87(2):1013\u201333.","journal-title":"Biophys J."},{"key":"2001_CR51","unstructured":"Lechuga-Ballesteros D, Kuo MC. Dry powder compositions having improved dispersivity. WO [Patent]. 2001;1:32144."},{"issue":"1","key":"2001_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/aic.690060104","volume":"6","author":"DH Charlesworth","year":"1960","unstructured":"Charlesworth DH, Marshall WR Jr. Evaporation from drops containing dissolved solids. AIChE J. 1960;6(1):9\u201323.","journal-title":"AIChE J."},{"issue":"2","key":"2001_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1081\/DRT-120017747","volume":"21","author":"EH Kim","year":"2003","unstructured":"Kim EH, Dong Chen X, Pearce D. On the mechanisms of surface formation and the surface compositions of industrial milk powders. Dry Technol. 2003;21(2):265\u201378.","journal-title":"Dry Technol."},{"issue":"2","key":"2001_CR54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jfoodeng.2008.10.020","volume":"94","author":"EHJ Kim","year":"2009","unstructured":"Kim EHJ, Chen XD, Pearce D. Surface composition of industrial spray-dried milk powders. 2. Effects of spray drying conditions on the surface composition. J Food Eng. 2009;94(2):169\u201381.","journal-title":"J Food Eng."},{"key":"2001_CR55","first-page":"W4093","volume":"4","author":"MC Kuo","year":"2002","unstructured":"Kuo MC, Tep V, Gordon M, Schiavone H, Charan C, Lechuga-Ballesteros D. Preparation of stable and dispersible dry powder aerosol formulations by spray drying. AAPS PharmSci. 2002;4:W4093.","journal-title":"AAPS PharmSci."},{"key":"2001_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jamp.2020.1593","volume":"33","author":"FJ Kamga Gninzeko","year":"2020","unstructured":"Kamga Gninzeko FJ, Valentine MS, Tho CK, Chindal SR, Boc S, Dhapare S, et al. Excipient enhanced growth aerosol surfactant replacement therapy in an in vivo rat lung injury model. J Aerosol Med Pulm Drug Deliv. 2020;33:1\u20139.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"issue":"2-3","key":"2001_CR57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0925-4439(98)00068-4","volume":"1408","author":"J P\u00e9rez-Gil","year":"1998","unstructured":"P\u00e9rez-Gil J, Keough KM. Interfacial properties of surfactant proteins. Biochim Biophys Acta Mol Basis Dis. 1998;1408(2-3):203\u201317.","journal-title":"Biochim Biophys Acta Mol Basis Dis."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-02001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-021-02001-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-02001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T15:04:19Z","timestamp":1675177459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-021-02001-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["2001"],"URL":"https:\/\/doi.org\/10.1208\/s12249-021-02001-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Virginia Commonwealth University is currently pursuing patent protection of EEG aerosol delivery, LV-DPI aerosol generation devices, and patient interfaces, which if licensed may provide a future financial interest to the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"136"}}